New hope for tough cancers: testing a Triple-Threat treatment
NCT ID NCT05383482
Summary
This study tested a new three-drug combination (afuresertib, sintilimab, and chemotherapy) for people with advanced solid tumors that had stopped responding to prior immunotherapy. The goal was to find a safe, effective dose and see if this combination could help control cancer growth in patients with specific cancers like lung, cervical, and stomach cancer. It involved a small group of patients to first check safety, then a larger group to measure how well the treatment worked.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
-
Chongqing Cancer Hospital
Chongqing, Chengdu, China
-
Jilin Cancer Hospital
Changchun, Jilin, China
-
West China Second University Hosital, Sichuan University
Chengdu, Sichuan, China
-
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China
Conditions
Explore the condition pages connected to this study.